The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

G Dornadula, 1999, Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy., JAMA, 282, 1627, 10.1001/jama.282.17.1627

F Maldarelli, 2007, ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia., PLoS Pathog, 3, e46, 10.1371/journal.ppat.0030046

S Palmer, 2008, Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy., Proc Natl Acad Sci U S A, 105, 3879, 10.1073/pnas.0800050105

M Coiras, 2009, Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs., Nat Rev Microbiol, 7, 798, 10.1038/nrmicro2223

JB Dinoso, 2009, Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy., Proc Natl Acad Sci U S A, 106, 9403, 10.1073/pnas.0903107106

D McMahon, 2010, Short Course Raltegravir Intensification Does Not Reduce Persistent Low Level Viremia in Patients Suppressed on Combination Antiretroviral Therapy., Clin Infect Dis, 50, 912, 10.1086/650749

RT Steigbigel, 2008, Raltegravir with optimized background therapy for resistant HIV-1 infection., N Engl J Med, 359, 339, 10.1056/NEJMoa0708975

JL Lennox, 2009, Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial., Lancet, 374, 796, 10.1016/S0140-6736(09)60918-1

S Palmer, 2003, New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma., J Clin Microbiol, 41, 4531, 10.1128/JCM.41.10.4531-4536.2003

LT Clement, 1990, Novel immunoregulatory functions of phenotypically distinct subpopulations of CD4+ cells in the human neonate., J Immunol, 145, 102, 10.4049/jimmunol.145.1.102

C Rabian-Herzog, 1992, Characterization of lymphocyte subpopulations in cord blood., Bone Marrow Transplant, 9, 64

U Dianzani, 1994, Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule., J Immunol, 153, 952, 10.4049/jimmunol.153.3.952

DV Havlir, 2003, Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years., J Virol, 77, 11212, 10.1128/JVI.77.20.11212-11219.2003

AR Sedaghat, 2007, Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART., PLoS Pathog, 3, e122, 10.1371/journal.ppat.0030122

TL Kieffer, 2004, Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads., J Infect Dis, 189, 1452, 10.1086/382488

MJ Buzon, 2010, HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects., Nat Med, 16, 460, 10.1038/nm.2111

PW Hunt, 2003, T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy., J Infect Dis, 187, 1534, 10.1086/374786

M Goicoechea, 2006, Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA., J Infect Dis, 194, 29, 10.1086/504718

RT Gandhi, 2006, Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384., J Acquir Immune Defic Syndr, 42, 426, 10.1097/01.qai.0000226789.51992.3f

PY Hsue, 2009, Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis., AIDS, 23, 1059, 10.1097/QAD.0b013e32832b514b

DD Richman, 2009, The challenge of finding a cure for HIV infection., Science, 323, 1304, 10.1126/science.1165706